MilliporeSigma
  • Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.

Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.

Journal of neuroimmunology (2014-09-30)
Lamprini Skriapa, Paraskevi Zisimopoulou, Nikolaos Trakas, Eirini Grapsa, Socrates J Tzartos
ABSTRACT

Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD) as immunoadsorbent. We showed that two different immunoadsorbents, very efficiently and selectively depleted the MuSK antibodies from all tested sera, were stable during the procedure and were reusable. Furthermore, animal experiments showed that the treatment has no toxic effects to the animals. We conclude that the MuSK-ECD-mediated immunoadsorption can be used as an efficient antigen-specific therapy for MuSK-MG.

MATERIALS
Product Number
Brand
Product Description

Supelco
4-tert-Octylphenol monoethoxylate solution, 10 μg/mL in acetone, analytical standard
Sigma-Aldrich
Cyclophosphamide monohydrate, bulk package
Sigma-Aldrich
Cyclophosphamide monohydrate, ISOPAC®
Supelco
Cyclophosphamide monohydrate, analytical standard